Breckenridge Recalls One Lot of Propranolol Capsules
Breckenridge Pharmaceutical is voluntarily recalling one lot of propranolol hydrochloride extended-release capsules, 60 mg, over potential metal contamination, the company announced on Monday, November 16, 2026. The lot is PK25110035, in 100-count bottles with NDC 51991-817-01 and a May 2029 expiration. Anyone holding it should stop taking it and call their doctor.
One lot, one strength, one check: read the lot number on the bottle. If it says PK25110035, the instruction isn't to finish the bottle carefully — it's to stop, call your doctor for a replacement, and take the rest back to the pharmacy.
Breckenridge Pharmaceutical is voluntarily recalling one lot of propranolol hydrochloride extended-release capsules, USP 60 mg, because the capsules may be contaminated with metal, the company announced on Monday, November 16, 2026. The recall runs to the consumer level, which means it reaches past pharmacies to the people holding the bottle. The capsules were manufactured by Adare Pharma Solutions.
The affected product is narrow and identifiable. It's lot PK25110035, sold in 100-count bottles under NDC 51991-817-01, with an expiration date of May 2029. Breckenridge distributed the lot nationwide to wholesalers and pharmacies between October 26 and November 4, 2026. No other lot and no other strength is named in the recall, so the lot number on the bottle is the whole test.
The stated risk is physical, not chemical. Swallowing product from the affected lot could cause cuts to soft tissue in the mouth, esophagus, stomach or intestine, the company said. Breckenridge said the lot shared intermediate material that's suspected to be the source of metal contamination found in a separate lot, and that separate lot was never released to market. As of the announcement, the company isn't aware of any adverse events assessed as related to this recall.
Propranolol is a beta blocker, a long-established prescription drug used to treat high blood pressure and other heart conditions, and to prevent migraine headaches. That matters for how a recall like this one should be handled: patients aren't told to simply quit a heart medication on their own. The company's instruction pairs the two steps — stop taking capsules from this lot, and contact your physician or health care provider for medical advice and replacement instructions.
The rest of the instruction is mechanical. Return any unused portion of the affected product to the pharmacy where you got it. Wholesalers, pharmacies and other retailers are told to check inventory, quarantine any affected product, and not distribute or dispense it, and businesses that passed the lot further down the chain should notify their accounts down to the retail level.
Questions about the recall go to Qualanex, Breckenridge's recall service provider, at 1-855-736-0807, Monday through Friday from 9:00 a.m. to 5:00 p.m. Eastern Time, or by email at [email protected]. Anyone who believes they've had a problem from the product can report it to the FDA's MedWatch program online or at 1-800-332-1088. Breckenridge said the recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
Recalls of a single lot live or die on whether the people holding the bottle ever see the lot number. This one's identifiers fit in one line — propranolol extended-release, 60 mg, lot PK25110035, May 2029 — and the check takes ten seconds at a medicine cabinet. If the numbers match, the bottle goes back to the pharmacy and the replacement conversation happens with a doctor, not with the remaining capsules.
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.